Paper Details

  1. Home
  2. Paper Details

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Author: AviviIrit, BergDeborah, EinseleHermann, EsseltineDixie-Lee, GuptaNeeraj, HariParameswaran, HájekRoman, KumarShaji, LiberatiAnna M, LinJianchang, LonialSagar, LudwigHeinz, MassziTamas, MateosMaria-Victoria, MinnemaMonique C, MoreauPhilippe, RichardsonPaul G, RomerilKenneth, ShustikChaim, SpencerAndrew

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Ixazomib, an oral proteasome inhibitor, is approved for the treatment of patients with multiple myeloma who have received at least one prior therapy. A clinical trial showed that ixazomib significantly improved progression-free survival compared to placebo. Common side effects included thrombocytopenia, nausea, vomiting, diarrhea, constipation, rash, peripheral neuropathy, peripheral edema, and back pain.
Paper Details　
Original Abstract of the Article :
The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the globa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574012/

データ提供：米国国立医学図書館（NLM）

Ixazomib: A New Frontier in Multiple Myeloma Treatment

The fight against multiple myeloma, a type of blood cancer, is an ongoing battle. This research focuses on the use of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone (Rd) for the treatment of relapsed/refractory multiple myeloma. The authors reviewed safety data from a Phase III clinical trial, TOURMALINE-MM1, which compared ixazomib-Rd (IRd) to placebo-Rd. The study revealed that IRd significantly improved progression-free survival compared to placebo-Rd, with manageable toxicities. This research sheds light on the efficacy and safety profile of ixazomib in the treatment of multiple myeloma.

Ixazomib: A Promising New Weapon in the Arsenal

The TOURMALINE-MM1 study demonstrated that ixazomib, in combination with Rd, significantly improved progression-free survival for patients with relapsed/refractory multiple myeloma. While some toxicities were observed, they were generally manageable with supportive care, suggesting that IRd offers a valuable treatment option with a favorable safety profile.

Navigating the Desert of Myeloma Treatment

Multiple myeloma is a complex and challenging disease. This research provides valuable insights into the efficacy and safety of ixazomib in the treatment of relapsed/refractory multiple myeloma. It's important to discuss your treatment options with your doctor to determine the best course of action for your individual needs and ensure that you receive the optimal care.

Dr.Camel's Conclusion

This research offers a glimmer of hope for patients battling multiple myeloma. Ixazomib, in combination with Rd, shows promise as a safe and effective treatment option for relapsed/refractory disease. It's a testament to the ongoing efforts to develop new and innovative therapies to combat this challenging cancer.

Date :
  1. Date Completed 2017-09-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28485007

DOI: Digital Object Identifier

PMC5574012

Related Literature

Article Analysis
・Side Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.